EDIT vs CRSP
EDIT and CRSP side by side — valuation & fundamentals (public data).
Key statistics
| Metric | EDITEDITAS MEDICINE, INC. | CRSPCRISPR THERAPEUTICS AG |
|---|---|---|
| Market cap | $417.74M | $5.05B |
| P/S | 10.3x | 1438.0x |
| Revenue growth (YoY) | 25.4% | -90.6% |
| Earnings growth (YoY) | 32.5% | -58.8% |
| EBIT margin | -394.9% | -18933.6% |
| ROE | -152.0% | -33.3% |
| ROIC | — | -32.6% |
| 1y total return | -3.9% | -14.6% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: EDIT vs CRSP
| 지표 | EDIT | CRSP |
|---|---|---|
| 최종 가치 | $1.9K | $37.1K |
| 총수익률 | -80.5% | +270.6% |
| CAGR | -15.2% | +14.1% |
| 변동성 | 84.3% | 64.0% |
| 샤프 | 0.16 | 0.46 |
| 소르티노 | 0.25 | 0.71 |
| 최대 낙폭 | -98.9% | -85.1% |
공통 거래일 2490일 기준, 2016-10-19 → 2026-09-16 · 무위험수익률 4.11% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)